Please read the important disclaimer at the following link before proceeding further on this page. The administrator of this forum is not a doctor nor licensed or experienced in any aspect of the health care industry.
https://www.covid-19forum.org/index.php?topic=227.0[edit add] In 2020 there were few published studies on monoclonal antibodies.
By mid-2021 there are now a number of studies that demonstrate considerably positive results on these
expensive but apparently effective patented therapies. Please review the studies at the following links for the - also
NIH recommended and thus hospitals shouldn't really be hesitant to administer - monoclonal antibodies (particularly considering
less effective Remdesivir that even the
WHO recommended against using regardless of the severity of disease.):
Please visit these important links:
https://c19regn.com/casirivimab/imdevimab studies show:
early treatment 72% improvement, late treatment 6% imp, pre-exposure prophylaxis 94% effective, viral clearance 69% effectivehttps://c19regn.com/rmeta.htmlhttps://c19ly.com/bamlanivimab studies show:
early treatment 76% improvement, late treatment 18% imp, all studies 57% improvementWhat stage of infection should one seek an intravenous infusion of monoclonal antibodies?
An internet search suggests within 7-10 days of the onset of symptoms:
https://duckduckgo.com/?q=monoclonal+antibodies+within+7+days+of+symptoms&t=hy&va=g&ia=web"
Monoclonal antibody therapy needs to be given as soon as possible after symptoms start to work—ideally within 4 days and no longer than 7 days."
https://www.unchealthcare.org/coronavirus/monoclonal-antibody-infusion-therapy/"The trial enrolled outpatients who had presented within 7 days after the onset of symptoms and within 72 hours after a positive result....."
https://www.nejm.org/doi/full/10.1056/NEJMe2034495Like most medicines not without side effects:
https://www.regeneron.com/downloads/treatment-covid19-eua-fact-sheet-for-patient.pdfI've heard of at least one hospital that puts their patients on Remdesivir while telling the patient if the condition worsens they would put them on monoclonal antibodies. Does that make sense considering all of the trials on monoclonal antibodies listed above and websites suggest using within the first 7-10 days? Monoclonal antibodies are antiviral, so after the first 7-10 days or so from the onset of symptoms the virus is pretty much done replicating and the immune system is entering an inflammatory phase in reaction do dead viral debris.
Another example demonstrating
you have to take your health care into your own hands! You have to forcefully advocate for your loved one if in the hospital/system. The abject ignorance of "professionals" is appalling, particularly in regard to early treatment protocols and in particular ivermectin, which has been shown to be effective in all stages of COVID as well as useful as an adjunct for other therapies that it isn't contraindicated for - if any.
Monoclonal antibodies are a little inappropriate for this forum section, even though they are an early treatment antiviral, because they are a bit of an outpatient-inpatient drug since they are infused intravenously.
[end edit]
_______________________________________________________
edit add:
see later video in second panel for update since these have apparently improved._______________________________________________________
Continuing with
less relevant post of February 10, 2021 if you want to spend your time that way:
Scroll to the 12:05 mark in the following video link for opinion on monoclonal antibodies:
Dr Peter McCullough: "
For the first antibody provided by Lily there was only three patients difference between the placebo and the active treatment - three. And for the Regeneron antibody pair there were only two patients difference. So these therapies were basically approved on a wing and a prayer. And what Dr. Marik has done and Dr Scheim has done is they have shown clear and convincing evidence that
with existing therapies used in combination, that there's a far greater weight of evidence than these very expensive monoclonal antibodies which are not practical or available that our authorities have approved."
https://www.youtube.com/watch?v=Gq0Js3S-YGU&feature=youtu.beCompare the value of that expensive $1250 drug, to the up to 100% early treatment efficacy of $20 Ivermectin multi-drug therapy:
https://www.covid-19forum.org/index.php?topic=461.0or the up to 100% early treatment efficacy of $20 hydroxychloroquine multi-drug therapy:
https://www.covid-19forum.org/index.php?topic=359.0______________________________________
https://trialsitenews.com/infectious-diseases-society-of-america-cautious-with-lillys-monoclonal-antibody-product-for-covid-19-recommends-against-routine-usage/"Although there has been considerable buzz around the recent U.S. Food and Drug Administration (FDA) acceptance of
Eli Lilly’s monoclonal antibody bamlanivimab (LYCoV555) for emergency use authorization (EUA) targeting COVID-19, the
Infectious Diseases Society of America (IDSA) recommended against the routine use of this novel drug. Although the group of physicians is open to use
if the patient has a thorough understanding of the benefits as well as the risks, the strong statement certainly sends a message. Note, TrialSite appeared to be the only media platform to report on the total price the
U.S. government was paying Lilly for this highly experimental drug: at $1,250 per vial for a total of $375 million for the first purchase of 300,000 vials with an option (at same price) for 650,000 vials worth up to $1.2 billion in sales.
TrialSite follows with a brief breakdown of this recent position written by Marie Rosenthal IDSA published in Infectious Disease Special Edition (IDSE).
